InBody Co.,Ltd

KOSDAQ-041830
KOSDAQ
Healthcare Medical - Specialties
Global Rank
#18919
Country Rank
#582
Market Cap
257.31 M
Price
20.31
Change (%)
0.18%
Volume
46,689

InBody Co.,Ltd's latest marketcap:

257.31 M

As of 08/13/2025, InBody Co.,Ltd's market capitalization has reached $257.31 M. According to our data, InBody Co.,Ltd is the 18919th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 257.31 M
Revenue (ttm) 153.53 M
Net Income (ttm) 22.74 M
Shares Out 12.67 M
EPS (ttm) 1.77
Forward PE 11.29
Ex-Dividend Date 03/28/2025
Earnings Date 08/14/2025
Market Cap Chart
Data Updated: 08/13/2025

InBody Co.,Ltd's yearly market capitalization.

InBody Co.,Ltd has seen its market value drop from ₩428.8 B to ₩354.67 B since 2014, representing a total decrease of 17.29% and an annual compound decline rate (CAGR) of 1.77%.
Date Market Cap(₩) Market Cap(USD) Change (%) Global Rank
08/13/2025 ₩354.67 B $257.31 M 19.42% 18919
12/30/2024 ₩297.52 B $199.34 M -9.91% 19013
12/28/2023 ₩330.23 B $254.28 M 25.5% 17418
12/29/2022 ₩263.14 B $207.88 M -12.74% 17810
12/30/2021 ₩301.57 B $253.32 M 33.43% 17458
12/30/2020 ₩226.02 B $207.93 M -28.16% 16562
12/30/2019 ₩314.59 B $270.55 M 7.52% 13288
12/28/2018 ₩292.57 B $260.39 M -45.89% 12583
12/28/2017 ₩540.65 B $502.81 M 47.1% 10376
12/29/2016 ₩367.54 B $301.38 M -53.45% 11181

Company Profile

About InBody Co., Ltd.

InBody Co., Ltd. is a global leader in body composition analysis solutions, dedicated to providing advanced health assessment tools.

Products and Solutions

The company offers a diverse range of products, including:

  • Body composition analyzers
  • Blood pressure monitors
  • Stadiometers
  • Body water analyzers
  • InBody dial and bands

Applications

InBody's products are widely used across various medical and wellness fields, such as:

  • Bariatric care
  • Cardiology and diabetes management
  • Frailty and aging studies
  • ICU monitoring
  • Lymphedema treatment
  • Nephrology and oncology
  • Sports medicine and rehabilitation

Company Background

Originally founded as Biospace Co., Ltd. in 1996, the company rebranded to InBody Co., Ltd. and is headquartered in Seoul, South Korea.

Frequently Asked Questions

  • What is InBody Co.,Ltd's (KOSDAQ-041830) current market cap?
    As of 08/13/2025, InBody Co.,Ltd (including the parent company, if applicable) has an estimated market capitalization of $257.31 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • InBody Co.,Ltd global market capitalization ranking is approximately 18919 as of 08/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.